China Develops New Heterogeneous Type II Collagen Vaccine

Chinese People's Liberation Army 307 Hospital immunology laboratory and National Center of Biomedical Analysis' immunological analysis laboratory have developed the world's first heterogeneous type II collagen therapeutic gene vaccine. This is a breakthrough in the country's rheumatoid arthritis biotherapy field, signifying China's therapeutic gene vaccine research has joined the top ranks in the field. Patents have been filed in the U.S., U.K., France, Germany, Japan and China and are in the public appraisal stage. Recently, the vaccine was granted research funds from the national major new drug innovation program and included as an innovative drug with self-developed intellectual property rights. (Click here for more - Chinese language)